Author: Ravi Shankar

With new leadership and a renewed sense of purpose, Cycurion is bringing mission-focused tenacity and next-generation technology across the company, including to Digital Ally’s proven product line.

MCLEAN, Va., Oct. 21, 2026 (GLOBE NEWSWIRE) — Cycurion, Inc., a Delaware corporation (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading AI-driven, tech-enabled cybersecurity solutions provider, today announced continued growth in its Digital Ally video solutions business. Over the past 30 days, including October activity, Digital Ally has secured approximately $383,000 in new and expanded contracts with law enforcement agencies across the Midwest.

This activity comes as Cycurion’s team of former Special Operations and Intelligence Community professionals leads a broader renewal of the Company’s structure and strategy.

“When we acquired Digital Ally, we inherited a talented, dedicated workforce,” said L. Kevin Kelly, Chairman and CEO of Cycurion. “The same caliber of talent that is rebuilding Cycurion is now driving a broader revitalization across the Company. Our teammates from the Special Operations and Intelligence communities bring a distinct mindset grounded in tenacity and a deep understanding of cutting-edge technology. They also understand, better than most, the importance of reliable equipment. That influence is already visible across the organization.”

Over the past 30 days, Digital Ally has secured approximately $383,000 in new and expanded contracts spanning in-car video systems, body-worn cameras, cloud-based digital evidence management, and expansions for existing customers. Solutions include the EVO HD and EVO Core in-car video systems, FirstVu Pro body-worn cameras, and multi-year unlimited cloud plans (typically 5-year/90-day). Several agencies funded purchases upfront, including through grant sources, while others extended existing plans and added equipment to support ongoing operations.

A consistent theme among these wins is agencies’ preference for Digital Ally’s innovative video products, responsive customer service, and ability to design solutions around each department’s specific requirements.

“These results show the continued demand for practical, high-quality video and evidence solutions among law enforcement agencies. And our products continue to improve,” said L. Kevin Kelly. “Agencies are choosing Digital Ally because the products work in the field, the support is responsive, and we build around what each department actually needs.”

This momentum builds on the strong foundation established with the Digital Ally acquisition and reinforces Cycurion’s broader strategy of delivering integrated public safety technologies. The recent contracts add to Digital Ally’s established base of more than 800 law enforcement, municipal, and public safety clients. Combined with Cycurion’s AI-driven cybersecurity and managed services capabilities, the portfolio positions the Company to offer comprehensive solutions that protect video systems, evidence, and the networks that support them.

About Cycurion, Inc.

Based in McLean, Virginia, Cycurion, Inc. (NASDAQ: CYCU) is an AI-driven, tech-enabled provider of cybersecurity, IT and public safety technology solutions. The Company specializes in cybersecurity, program management and business continuity, and uses its AI-enhanced platform and experienced team to help clients protect their operations. Together with its subsidiaries — Axxum Technologies LLC, Cloudburst Security LLC, Cycurion Innovation, Inc. and Cycurion Digital Ally — Cycurion serves government, healthcare, law enforcement and corporate clients. Through Digital Ally, the Company also provides in-car video systems, body-worn cameras and cloud-based digital evidence management to more than 800 law enforcement, municipal and public safety agencies. For more information, visit www.cycurion.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business, including its Digital Ally video solutions business, and the Company’s strategy and vision.

Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Such statements include, but are not limited to, statements regarding continued growth and momentum in the Digital Ally business; the expected value, duration, and performance of the contracts described in this press release; continued demand for the Company’s video and digital evidence solutions among law enforcement agencies; the continued improvement of Digital Ally’s products; the renewal of the Company’s structure and strategy under its leadership team; the anticipated benefits of the Digital Ally acquisition; the Company’s ability to deliver integrated public safety technologies and to offer comprehensive solutions that protect video systems, evidence, and the networks that support them; and other statements that are not historical facts. Words such as “aim,” “continue,” “will,” “may,” “could,” “should,” “expect,” “plans,” “intend,” “designed to,” “anticipate,” “believe,” “estimate,” “potential,” “positions,” “seek,” and similar expressions are intended to identify such forward-looking statements.

All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Cycurion and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: the risk that contracts are terminated, reduced, delayed, or not renewed, or that customers do not exercise extensions or expansions; dependence on federal, state, and local government budgets, appropriations, and grant funding; the timing of revenue recognition under multi-year cloud and service plans; the Company’s ability to successfully integrate Digital Ally and realize the anticipated benefits of the acquisition; competition in the law enforcement video and digital evidence management market; supply chain, component availability, and manufacturing risks; product performance, reliability, and warranty matters; the Company’s ability to attract and retain key personnel, including its new leadership team; market acceptance of the Company’s combined video and cybersecurity offerings; the Company’s ability to fund its operations and growth; government contracting, procurement, and compliance requirements; cybersecurity incidents affecting the Company or its clients; any potential legal proceedings; and the future performance of the Company’s stock. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Cycurion with the U.S. Securities and Exchange Commission. Cycurion anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Cycurion assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Cycurion’s plans and expectations as of any subsequent date.

Cycurion Investor Relations:
(888) 341-6680
investors@cycurion.com

Cycurion Media Relations:
(888) 341-6680
media@cycurion.com

     Agreement signed at Sheikh Zayed Museum in Abu Dhabi pairs VivoPower’s powered land and data center infrastructure capabilities with Open Innovation AI’s sovereign AI orchestration and security platform.

     The partners see a sovereign AI opportunity of more than 40GW in Europe alone, across government administration, defense, medical, educational and financial services sovereign cloud and will target at least 1GW of capacity over the next three years, with further demand across the GCC and Asia.

     VivoPower to lead site development, power procurement and facility operations; Open Innovation AI to provide the orchestration, AI operations and security layer.

     Builds on Open Innovation AI’s track record, experience designing, deploying and operating sovereign AI platforms for government and enterprise environments and clients in the UAE.

LONDON, UK / ABU DHABI, UAE, Oct. 21, 2026 (GLOBE NEWSWIRE) — VivoPower PLC (Nasdaq: VIVO) (“VivoPower” or the “Company”), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that it has executed definitive heads of agreement (“Agreement”) with Open Innovation AI (“OI”), the UAE-based AI orchestration, operations and security platform company to jointly explore and develop secure sovereign AI Data Centers across the Nordics, Mainland Europe, the GCC and selective countries in Asia.

The Agreement was signed at Sheikh Zayed Museum in Abu Dhabi on Wednesday, 21 October 2026, in the presence of senior leadership from both companies. The signing in the UAE capital reflects Abu Dhabi’s growing role as a global hub for sovereign AI, and the ambition of both partners to take that model to new markets.

Demand for AI compute is growing faster than the power, land and platforms available to host it. Governments and enterprises increasingly want capacity that remains under their control, with sovereignty over infrastructure, data, models and AI services, supported by strong cyber security and governance. The collaboration combines VivoPower’s expertise in securing power and developing data center infrastructure with Open Innovation AI’s orchestration, AI operations and security capabilities.

Under the Agreement, the two companies will work together to originate and deliver AI data center projects with control and security embedded from design to operation. Open Innovation AI brings its Full Stack AI Fabric, combining orchestration and scheduling, AI and ML operations, agentic workflows, agent harness and AI security into one platform. VivoPower brings site sourcing and acquisition, site development, power and facility operations, and local market municipality and sovereign relationships.

What sovereign cloud means

Sovereign cloud is AI and cloud infrastructure that a nation, and the organizations it trusts, can fully control. In a conventional public cloud, data, models and operations can ultimately be subject to foreign jurisdiction, foreign-controlled operators or a single vendor’s technology. A sovereign cloud keeps every critical layer secure under local law and local control:

• Sovereign infrastructure: the land, power, buildings and compute are located in-country and owned or controlled by domestic or trusted partners.
• Data sovereignty: data is stored and processed within national borders, governed by local law and protected from extraterritorial access.
• Operational sovereignty: the platform is run, monitored and supported by trusted local teams, and can operate in private cloud, on-premises or fully air-gapped environments.
• Technology sovereignty: governments and enterprises control the software stack, models and security, without lock-in to any single foreign provider or hardware vendor.

Sovereign AI applies these principles across the full AI lifecycle, from GPU orchestration and model training to the AI applications and agents that power public services, critical national infrastructure, defense, healthcare, finance and industry.

A large and growing opportunity

Demand for sovereign AI capacity is accelerating rapidly at a time when sovereigns are realizing they have limited excess power for their own sovereign cloud needs, let alone to allocate to hyperscalers and AI companies. Governments are moving to secure their own compute, and power has become the prerequisite. Without secured, scalable power there can be no sovereign AI, which makes powered land the starting point of every sovereign AI project. In addition, governments need development partners to deliver the AI infrastructure and they need a technology and orchestration partner to deliver the sovereign cloud. Against this backdrop, VivoPower and Open Innovation AI see an initial opportunity of more than 40GW in Europe alone and will target at least 1GW of capacity over the next three years, with further demand across the GCC and Asia. Through VivoPower’s existing assets, Nordic pipeline and sovereign relationships, together with OI’s track record of orchestrating sovereign cloud solutions, the Partnership will seek to become the leading AI sovereign solution for governments in the target jurisdictions.

What the agreement covers

The Agreement sets out the framework for the collaboration. The parties intend to progress individual projects under separate, project-specific agreements, with definitive documentation to follow in due course.

As a first step, VivoPower has partnered with Open Innovation AI to deploy its software solutions, covering orchestration, AI operations and security, across VivoPower’s portfolio and Nordic pipeline.

Open Innovation AI’s role builds on the sovereign AI know-how it has developed in the UAE, one of the world’s earliest and most ambitious adopters of sovereign cloud. The company has designed, deployed and operated AI labs and platforms for government and enterprise environments where local control, security and operational governance are critical. That experience gives the partnership a practical foundation to support projects across the targeted jurisdictions.

A natural fit of ambitions

The partnership is also a natural fit of ambitions. VivoPower is pursuing large-scale growth as a global developer of AI-ready power and data center infrastructure for sovereigns. Open Innovation AI is expanding its orchestration and security platform well beyond the UAE into international markets. Together, the companies intend to combine powered infrastructure with the software layer required to run AI safely, efficiently and under full sovereign control.

The aim is simple: give nations and enterprises a faster path from powered land to production-ready AI capacity that remains secure, governed and locally controlled. This in turn will drive sovereign prosperity and national security.

Why the partnership is positioned to win

Today, most governments building sovereign AI capacity must bring together power developers, builders, hardware suppliers, cloud providers and software vendors themselves, and often still depend on foreign hyperscalers for the critical software layer. The US CLOUD Act means European sovereigns in particular need a neutral solution and those developed in Abu Dhabi are some of the most advanced in the world. VivoPower and Open Innovation AI offer a different model:

• One partner from site to service: a single, integrated offering that covers powered land, data center development and operations, and the orchestration, AI operations and security platform, with clear accountability from day one.
• Power where it is scarcest: access to power is now the main constraint on new AI capacity. VivoPower brings powered land and data center infrastructure across Norway, Finland and the UAE, and a pipeline of sites with access to low-cost power.
• A proven sovereign platform: Open Innovation AI has designed, deployed and operated its platform for government critical infrastructure and enterprise environments in the UAE, where local control, security and governance are essential.
• Independent and hardware-agnostic: the Sovereign AI Fabric runs across private cloud, on-premises and air-gapped environments and is not tied to any single hardware vendor or hyperscaler, so nations keep control of their technology choices.
• Faster time to production: pairing ready sites with a pre-integrated software stack shortens the path from energized site to production-ready AI capacity.
• Security by design: cyber security and governance are embedded from facility design through to the AI models and agents running on the platform.

A partnership across four regions

VivoPower and Open Innovation AI will focus on four regions where demand for sovereign AI capacity is accelerating:

• The Nordics: building on VivoPower’s existing asset in Mo i Rana, Norway and its proprietary pipeline across the Nordics.
• The GCC: building on Open Innovation AI’s home base in the UAE and VivoPower’s regional presence in Abu Dhabi to support national AI strategies across the Gulf and wider region.
• Mainland Europe: helping European governments and industry meet growing requirements for AI capacity, cyber security, data sovereignty and operational control under European governance.
• Selective Asian Countries: serving fast-growing markets investing in domestic AI capability, cyber-resilient infrastructure and strategic digital independence, in jurisdictions that are supportive of AI infrastructure development and where VivoPower has a sourcing advantage through low-cost power.

Alex Cuppage, Chief Investment Officer of VivoPower PLC, said: “VivoPower is committed to working with nations as their most trusted long-term and aligned AI infrastructure partner to deliver leading sovereign AI infrastructure. We believe that sovereigns who develop leading AI infrastructure, supported by a secure and full stack sovereign cloud solution will drive national prosperity and security. In most cases, allocations of a nation’s natural resources of power and water to sovereign cloud represents the highest and best use. The UAE is globally seen as one of the most advanced nations utilizing sovereign compute. We are delighted to establish this partnership with Open Innovation AI, a proven sovereign AI orchestration and security platform, offering governments and enterprises a complete path from site to secure AI service. Signing this agreement in Abu Dhabi, at the heart of the region’s AI ambition, is a fitting start. We are excited to work together with sovereigns across the Nordics, Mainland Europe, the GCC and Asia to help develop their compute power infrastructure, which will equate to national prosperity and national security.”

Kevin Chin, Executive Chairman and CEO, VivoPower PLC, said: “Sovereign AI needs more than power and buildings. It needs a trusted, secure platform to run on. Our partnership with Open Innovation AI lets VivoPower offer sovereigns a complete solution, from powered land to production-ready AI. It is an important step in building VivoPower into a leading independent sovereign AI infrastructure partner, and in creating long-term value for our shareholders across our existing portfolio and near-term pipeline.”

Dr. Abed Benaichouche, Co-Founder and CEO of Open Innovation AI, said: “Sovereign AI is not only about compute capacity; it is about securing and controlling the technology layer that allows governments and enterprises to run AI safely, locally and at scale. VivoPower shares our belief that every nation should control its own intelligence. Together, we can bring secure AI Data Centers online faster across the Nordics, Mainland Europe, the GCC and Asia, and take the UAE’s AI expertise to new markets.”

About VivoPower

Originally founded in 2014 and listed on Nasdaq since 2016, VivoPower is an award-winning B Corporation with data center and powered land infrastructure across Norway, Finland, and the United Arab Emirates. The Company’s mission is to be the independent, trusted partner for sovereign nations that develop and operate sustainable data center infrastructure, ensuring sovereign control over power, data, and national intelligence. In doing so, VivoPower helps sovereign nations bridge the gap between their energy assets and their AI ambitions by providing the Power-to-X infrastructure necessary to build and control their own domestic intelligence hubs.

About Open Innovation AI

Open Innovation AI is a UAE-based technology company helping enterprises adopt AI through its Sovereign AI Fabric, a hardware-agnostic platform for building, deploying, and operating AI. Runtime Fabric provides a production-ready Kubernetes foundation purpose-built for AI environments. Engine Fabric orchestrates GPUs and manages AI workloads from development through deployment. Agent Fabric helps organizations build and operate agentic applications. Security Fabric tests, governs, monitors, and secures AI models, agents, and applications. Designed for private cloud, on-premises, and air-gapped environments, the platform gives organizations control over their infrastructure, data, models, and AI operations.

Forward-Looking Statements

This communication includes certain statements that may constitute “forward-looking statements” for purposes of the U.S. federal securities laws. Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about the collaboration between VivoPower and Open Innovation AI, the deployment of Open Innovation AI’s software solutions across VivoPower’s portfolio and Nordic pipeline, including the Mo i Rana site, the negotiation and execution of definitive or project-specific agreements, the origination, development and delivery of AI data center projects in the Nordics, Mainland Europe, the GCC and Asia, the expected benefits of the collaboration, the size of the sovereign AI opportunity and of the parties’ potential project pipeline, demand for sovereign AI capacity, or the benefits of the events or transactions described in this communication. These statements are based on VivoPower’s management’s current expectations or beliefs and are subject to risk, uncertainty, and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive and/or regulatory factors, and other risks and uncertainties affecting the operation of VivoPower’s business. These risks, uncertainties and contingencies include changes in business conditions, fluctuations in customer demand, changes in accounting interpretations, management of rapid growth, intensity of competition from other providers of products and services, changes in general economic conditions, geopolitical events and regulatory changes, and other factors set forth in VivoPower’s filings with the United States Securities and Exchange Commission. Specifically in relation to the Heads of Agreement, the Heads of Agreement do not by themselves commit either party to any specific project, and there can be no assurance that project-specific agreements will be entered into, or that any project will proceed on the terms contemplated, on the anticipated timing, or at all. The development of any project is subject to, among other things, the availability of suitable sites, power and financing, customer and government demand, and regulatory and other approvals, the timing of which is outside the control of the Company. The information set forth herein should be read in light of such risks. VivoPower is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements whether as a result of new information, future events, changes in assumptions or otherwise.

Contact
Shareholder Enquiries
media@vivopower.com
press@openinnovation.ai

Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial

Sale Reinforces IMUNON’s Commitment to Its Core Strategy: Executing the Pivotal Phase 3 OVATION 3 Trial of IMNN-001

LAWRENCEVILLE, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an agreement to sell its rights to ThermoDox^®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc. (“VoxelDox”). Under the agreement, VoxelDox intends to advance the development of ThermoDox for the treatment of glioblastoma multiforme (GBM), a difficult-to-treat form of brain cancer. In exchange, IMUNON will receive an equity ownership stake in VoxelDox, payments of up to $16.5 million contingent upon meeting development milestones and significant royalties on future net sales of ThermoDox product following commercial approval.

Closing of the transaction is contingent upon VoxelDox completing a planned $2.5 million financing to support initiation of a Phase 1 clinical trial in patients with glioblastoma. The companies are announcing the agreement in advance of closing to provide visibility into the intended transaction and IMUNON’s continued strategic focus. The transaction enables IMUNON to retain potential long-term economic participation in ThermoDox while dedicating its financial and operational resources to advancing IMNN-001, the Company’s lead clinical program.

“We are pleased that ThermoDox has found a steward committed to advancing its development for the benefit of patients,” said Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “This agreement is consistent with our previously announced strategy to identify a development partner for this promising drug candidate and demonstrates our disciplined approach to portfolio management and capital allocation. By creating a path to realize future value from a legacy asset that has been fully written off, the transaction allows our organization to remain singularly focused on the successful execution of the pivotal Phase 3 OVATION 3 trial of IMNN-001 in frontline advanced ovarian cancer. We look forward to following VoxelDox’s progress as it works to advance this technology for patients with glioblastoma.”

Under the terms of the agreement, upon completion of VoxelDox’s financing, IMUNON will receive an equity interest of approximately 4.76% in VoxelDox, together with the potential to receive up to $16.5 million in aggregate development and sales-based milestone payments and tiered royalties ranging from 3.5% to 6% on net sales of ThermoDox-related products, if approved. IMUNON’s realization of any milestone or royalty payments, or of value from its equity position, is subject to VoxelDox’s success in financing, developing, and, if applicable, commercializing the asset, and there can be no assurance that any such value will be realized.

About VoxelDox Therapeutics, Inc.

VoxelDox Therapeutics is an emerging biotechnology company developing a precision oncology platform that integrates voxel-level measurement, heat-activated drug delivery, and image-guided treatment optimization. By combining spatially controlled thermal energy with temperature-sensitive therapeutics, VoxelDox aims to localize treatment where it is needed most. Initially focused on glioblastoma, the company is advancing a novel approach to targeted therapy with potential applications across a range of solid tumors. Moving beyond precision in diagnosis to precision in delivery, VoxelDox is advancing the future of precise medicine, one voxel at a time. For more information, visit www.voxeldoxtx.com.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas^®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine^®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently being studied in a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts

Investors
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com

NEWPORT NEWS, Va., Oct. 21, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Board of Directors has declared a quarterly cash dividend of $1.41 per share, a $0.03 increase over the $1.38 per share dividend paid in each of the prior four quarters. The $1.41 per share dividend will be payable on Dec. 11, 2026, to shareholders of record as of the close of business on Nov. 27, 2026.

About HII

HII is America’s Seapower Company. The nation’s largest shipbuilder, HII builds the manned and unmanned maritime systems and all-domain mission technologies that project U.S. and allied power around the world. With a more than 140-year history of advancing U.S. national security, HII is headquartered in Virginia and employs 45,000 people across three divisions. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:

Brooke Hart (Media)
brooke.hart@hii.com
202-264-7108

Christie Thomas (Investors)
christie.thomas@hii.com
757-380-2104

Company underscores substantial digital asset holdings, potential $225 million in additional cash capitalization, AI commercialization opportunities targeting over 20,000 retail locations, and an expanding intellectual property enforcement strategy with multibillion-dollar potential

CORNELIUS, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (NASDAQ: AMOD) (“Alpha Modus” or “the Company”) today provided an update on its digital asset holdings, ARIA, the Adaptive Retail Intelligence Architecture , patent enforcement program and Alpha Cash fintech platform.

The Company’s subsidiary, AMOD Tech Pte. Ltd., a Singapore private company limited by shares, holds Bitcoin valued at more than $250 million.* The Company’s subsidiary, Alpha Modus, Corp., is advancing ARIA and a patent enforcement program, while subsidiary Alpha Modus Financial Services, LLC oversees Alpha Cash. Management believes each business offers its own opportunity for long-term value creation.

“Alpha Modus today is fundamentally different from the company investors were evaluating just a few months ago,” said William Alessi, Chief Executive Officer of Alpha Modus. “Alpha Modus has substantially transformed its asset base. Separately, Alpha Modus, Corp. has successfully cleared important federal patent litigation hurdles and is advancing ARIA commercialization. These are tangible developments, each with its own potential to contribute to long-term enterprise value.”

Bitcoin Holdings Exceed $250 Million in Value,* With Warrants That Could Add $225 Million in Cash

On September 30, 2026, Alpha Modus completed a strategic transaction through which its wholly owned subsidiary, AMOD Tech Pte. Ltd., acquired 3,170 Bitcoin in connection with the issuance of approximately 51.6 million shares of common stock and accompanying warrants.

Based on Bitcoin’s market price as of October 20, 2026, the holdings represent more than $250 million in gross digital asset value, compared with an original agreed transaction valuation of approximately $225 million.

The transaction also included warrants to purchase an additional 51,621,560 shares, exercisable at $4.36 per share. The warrants are not exercisable on a cashless basis, and if exercised in full for cash under their existing terms, the warrants could provide approximately $225 million in additional gross proceeds to the Company.

“The Company’s Bitcoin transaction substantially expanded our asset base. It also established the potential to receive approximately $225 million in additional cash proceeds through warrant exercises. We believe these two components are important to understanding the scale of the transaction and the financial flexibility they could provide,” said Alessi.

ARIA Grocery Beta Moves Ahead With Greer’s Markets

Alpha Modus, Corp. is advancing ARIA, its artificial intelligence retail platform, through its strategic relationship with Circle the Wagons.

Circle the Wagons has identified a targeted pipeline of several hundred independent grocery retailers representing at least 20,000 retail locations, or roughly two-thirds of the U.S. independent grocery market.

Management believes the network represents a substantial opportunity for ARIA in one of the nation’s most fragmented retail sectors.

The recently announced beta testing agreement with Greer’s Markets, a 29-location grocer, is the first formal milestone in this initiative. Beta setup and baseline data collection is underway and progressing on schedule.

Over the next 9 months, Circle the Wagons intends to engage its identified retail prospects and pursue additional commercial agreements.

“Through Circle the Wagons, Alpha Modus, Corp. is addressing a substantial market with a defined strategy and an established network of prospective retail partners,” said Alessi. “Greer’s represents our first beta engagement, with a focus on translating this market opportunity into commercial adoption. We believe ARIA has the potential to become an important AI platform for independent retailers, materially improving operational efficiency and enhancing the customer experience.

Patent Cases Advance After Federal Court Rulings

On September 29 and 30, 2026, the U.S. District Court for the Eastern District of Texas adopted recommendations denying motions to dismiss filed by 7-Eleven, Johnson Controls and Sensormatic Electronics, Lowe’s, The Kroger Co. and Creative Realities in patent infringement cases brought by Alpha Modus, Corp. On August 21, 2026, the U.S. District Court for the Western District of Texas denied MNTN’s motion to dismiss under 35 U.S.C. § 101. The rulings allow the affected cases to advance.

Alpha Modus, Corp. has also identified dozens of additional potential infringement claims that have not yet been filed. Management intends to evaluate them through a phased enforcement strategy that could include licensing arrangements, negotiated resolutions and judicial remedies.

“The approach is deliberate: advance the existing cases and pursue additional opportunities where the facts and economics support doing so. The favorable federal court rulings have reinforced our confidence in the strength of our intellectual property enforcement strategy and our commitment to protecting the technologies we have developed. Management believes the potential scope of the intellectual property portfolio extends well beyond the litigation currently underway,” said Alessi.

Alpha Cash Builds Out Its Partner Program

Alpha Modus Financial Services, LLC oversees Alpha Cash, a financial technology platform focused on improving access to modern financial services for underserved and underbanked consumers. The first phase of the Alpha Cash partner portal is complete, and affiliate and reseller agreements are in place.

The portal is designed to give partners a dashboard for commissions and referrals, downloadable QR codes, payout requests and ready-made marketing materials. The team is also developing training programs for corporate and retail partners. Alpha Cash could begin onboarding affiliate partners in the coming weeks, subject to completion of testing and compliance reviews.

Three Businesses, Three Distinct Paths to Value

“AMOD Tech Pte. Ltd., Alpha Modus, Corp., and Alpha Modus Financial Services, LLC each represent distinct businesses with significant opportunities for long-term value creation,” concluded Alessi. “AMOD Tech Pte. Ltd. has established a substantial digital asset position with the potential for meaningful additional cash capitalization. Alpha Modus, Corp. continues to advance its AI commercialization strategy and an intellectual property enforcement program with opportunities extending well beyond its current litigation. Alpha Modus Financial Services, LLC is building a financial technology business addressing the needs of underserved consumers. Each business has its own assets, strategy, and potential to stand independently. We believe the public markets have yet to recognize the substantial underlying value of these businesses and the assets we have assembled. Our focus is on executing against these opportunities and demonstrating the value we believe we have created for our shareholders.”

* Based on 3,170 Bitcoin and market price of $82,525.80/BTC on October 20, 2026.

About Alpha Modus Holdings, Inc. (NASDAQ: AMOD)

Alpha Modus Holdings, Inc. (“Alpha Modus” or the “Company”) (NASDAQ: AMOD) is a vertical AI company focused on real-time, in-store shopper engagement and attribution. Its patented “closed-loop” retail AI framework, Sense → Decide → Deliver → Attribute, enables brands and retailers to measure the full impact of digital content, physical interactions, and transaction outcomes. Through subsidiaries like Alpha Modus Corp. and Alpha Modus Financial Services, LLC, the company is actively deploying technologies that merge artificial intelligence, retail media, and financial access across the physical retail landscape.

For more information, visit: www.alphamodus.com

Alpha Modus maintains a comprehensive overview of its patent portfolio on its website: https://amc.alphamodus.com/

For more information and to access Alpha Modus’ press room, visit: https://alphamodus.com/press-room/

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus’s actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus’s expectations with respect to future performance.

Alpha Modus Holdings, Inc. (“Alpha Modus”) cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contact Information

Investor Relations
Alpha Modus Holdings, Inc.
Email: ir@alphamodus.com
Website: www.alphamodus.com

Follow us on LinkedIn | Follow us on X

TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) announces that the Brazilian Supreme Court (“STF”) issued a decision on the request for suspension of provisional relief (Suspensão de Tutela Provisória) filed by Brazil’s Federal Public Prosecutor’s Office (“MPF”) concerning the Installation License (“LI”) for the Company’s Volta Grande Gold Project (the “Project”) in Pará, Brazil. The STF partially granted the MPF’s request, temporarily suspending the court ruling that had reinstated the effectiveness of the Project’s LI.

Clovis Torres, Chief Executive Officer of Belo Sun, commented: “The STF’s recognition of the relevance of the settlement hearing established by the TRF-1 is welcomed. We are advanced in our discussions with FUNAI with the settlement agreement submitted to TRF-1 and are confident that the parties will reach an agreement in the best interests of all stakeholders.”

The STF decision provides that the LI will remain suspended until the agreement reached between Belo Sun and Brazil’s National Foundation of Indigenous Peoples (“FUNAI“) during the conciliation proceedings receives judicial approval from Brazil’s Federal Regional Court of the 1st Region (the “TRF-1“). The agreement has already been submitted to the TRF-1 for approval, which remains pending.

The Company notes that, notwithstanding the pending judicial approval of the agreement, the parties have already been complying with their respective obligations under the agreement, including Belo Sun’s commitment to refrain from carrying out any physical interventions at the Project site. Belo Sun remains committed to the ongoing conciliation process and will continue its discussions with FUNAI and the Indigenous communities.

About the Company

Belo Sun is a Canadian-based mining company with a portfolio of gold-focused properties in Brazil. The Company is currently focused on the development of the Volta Grande Gold Project. Belo Sun trades on the Toronto Stock Exchange under the symbol “BSX” and on the OTCQX under the symbol “BSXGF”.

For more information, please visit www.belosun.com or contact Investor Relations at info@belosun.com or 1-888-516-4171.

Caution regarding forward-looking information:

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, the continued advancement of the Project, the conciliation process with FUNAI and the ongoing review and update of the Project’s studies. Forward-looking information is based on the opinions and estimates of management as of the date such information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. These factors include, without limitation, actions by the MPF and other parties, rulings or orders of the STF or other courts, changes in the regulatory environment, risks related to the ability of the Company to attract and retain qualified personnel, the ability of the Company to advance the Project to the construction phase, and other risks described in the Company’s filings with Canadian securities regulatory authorities, including the Company’s most recent Annual Information Form. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.

Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials

SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety and efficacy, today announced that it is extending its human tissue platform beyond toxicology, the core of its business today, with efficacy testing services built on NAMkind™ disease models of the liver and intestine. The disease models are built with cells from patient donors, so they carry features of the disease itself. Drug developers can measure whether a candidate acts on those disease features in human tissue before it enters clinical trials. VivoSim offers efficacy testing alongside toxicology on its liver and gastrointestinal (GI) models.

The move builds on demonstrated disease model excellence already demonstrated. Its intestinal efficacy platform, built in part from cells of patients with ulcerative colitis or Crohn’s disease, received a “Poster of Distinction” award at Digestive Disease Week in May 2025, in work showing that the platform responds to clinically used therapeutics. VivoSim has also used its human disease models to identify new molecular targets that drive inflammatory bowel disease (IBD) and to explore how known drugs act.

Lack of efficacy is the most common reason drug candidates fail in clinical trials. In an analysis of more than 28,000 clinical trials stopped before reaching their endpoints, more than twice as many were stopped for negative results or lack of efficacy as for safety (Razuvayevskaya et al., Nature Genetics, 2024).

“Toxicology is the core of our business today, and it will remain a core service,” said Keith Murphy, Executive Chairman of VivoSim Labs. “Our customers often need help with whether a candidate is likely to work, because that is where many drugs fall short in the clinic. Disease models let us address that question on the same human tissue platform we already use for safety, but leveraging patient-derived diseased cell sources so a customer can learn more before committing a program to clinical trials. We believe disease models could more than double our addressable market.”

NAMkind™ Disease Models

• Liver (MASH): The NAMkind™ MASH disease model co-cultures healthy human liver cells with stellate, Kupffer, and endothelial cells from a donor with metabolic dysfunction-associated steatohepatitis (MASH), producing steatotic tissue with fibrosis. Compounds are dosed repeatedly over 14 or 21 days, with readouts for fibrosis and liver function. Cell-health markers measured in the same study separate an anti-fibrotic effect from cell damage.
• Intestine (IBD): The NAMkind™ IBD disease model is built from colon and small-intestine organoids derived from donors with ulcerative colitis and Crohn’s disease, with twelve donors currently available. It measures barrier integrity, inflammation, and fibrosis in the same well and reports results donor by donor. A healthy tissue comparator arm is available.
• Pharmacodynamic (PD) & Target Biomarker Profiling: The platform evaluates target engagement, gene expression panels, cytokine profiling, extracellular matrix turnover markers, and other relevant biomarkers across donor tissues, enabling sponsors to map mechanism-of-action and dose-response relationships alongside functional efficacy readouts.

In both models, each study runs the client’s compound alongside an approved or clinically validated reference compound in the same donor tissue, such as resmetirom in the MASH model or tofacitinib or upadacitinib in the IBD model. In results VivoSim has published for the IBD model, JAK inhibitors that look alike on paper had different effects on fibrosis, barrier function and inflammation, and methotrexate, a clinically used anti-inflammatory, reduced a fibrosis marker in a dose-dependent way in both Crohn’s patient models tested.

“By leveraging patient-derived donor tissues, our disease platforms preserve the complex multiomic signatures and heterogeneous phenotypes seen in real-world clinical populations,” said Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs. “Crucially, we can now evaluate candidate compounds not only for primary disease endpoints like fibrosis and barrier repair, but also for target-specific pharmacodynamic biomarkers. This dual capability allows drug developers to confirm both functional human efficacy and underlying drug mechanism on the exact same platform before entering clinical trials.”

About VivoSim Labs

VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s cash on hand, revenue growth guidance and the Company’s progress in marketing contract research services using NAMs models to pharmaceutical companies. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. 

Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.

TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) announced today the appointment of Daan Dijkhuizen as its Chief AI Officer and a member of Constellation’s leadership team.

Mr. Dijkhuizen is currently the Chief Executive Officer of the Topicus Operating Group within Topicus.com Inc., and Managing Partner of VMS Ventures, Constellation’s venture arm. Mr. Dijkhuizen will continue in both of those roles alongside his new position as Chief AI Officer.

As the Chief AI Officer for Constellation, Mr. Dijkhuizen will focus primarily on expanding the role of VMS Ventures as Constellation’s vehicle for investing in AI-native vertical market software businesses. The role also includes supporting business units across the Constellation group of companies, as those businesses apply AI in their products and internal operations, with appropriate controls for quality, safety and compliance. Mr. Dijkhuizen will also support and encourage the sharing of best practices across Constellation’s operating groups.

About Constellation Software Inc.

Constellation’s common shares are listed on the Toronto Stock Exchange under the symbol “CSU”. Constellation acquires, manages and builds vertical market software businesses.

For further information:

Jamal Baksh

Chief Financial Officer

(416) 861-9677

info@csisoftware.com www.csisoftware.com

AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) — FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, software, and engineering services, today announced it will report its third quarter 2026 financial results before market open on Wednesday, November 4, 2026.

A conference call for members of the investment community will be held at 8:30 a.m. E.T. that same day, during which the Company will discuss its third quarter 2026 results, its outlook and other business items. This call will be webcast and can be accessed within the Investor Relations section of the FTC Solar corporate website at investor.ftcsolar.com. A replay of the conference call will also be available on the website for 30 days following the webcast.

About FTC Solar, Inc.
Founded in 2017 by a group of renewable energy industry veterans, FTC Solar is a leading provider of solar tracker systems, technology, software, and engineering services. Solar trackers significantly increase energy production at solar power installations by dynamically optimizing solar panel orientation to the sun. FTC Solar’s innovative tracker designs provide compelling performance and reliability, with an industry-leading installation cost-per-watt advantage. 

FTC Solar Investor Contact:
Bill Michalek 
Vice President, Investor Relations 
FTC Solar
T: (737) 241-8618 
E: IR@FTCSolar.com

PLAINVIEW, N.Y., Oct. 21, 2026 (GLOBE NEWSWIRE) — Veeco Instruments Inc. (NASDAQ: VECO) plans to release its third quarter 2026 financial results after the market closes on Wednesday, November 4, 2026. The company will host a conference call to review these results starting at 5:00 PM ET that day.

To join the call, dial (+1) 888-396-8049 (toll-free) or (+1) 416-764-8646. Participants may also access a live webcast of the call by visiting Veeco’s investor relations website at ir.veeco.com. A replay of the webcast will be made available on the Veeco website beginning at 8:00 PM ET that same evening.

About Veeco
Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our laser annealing, ion beam, metal organic chemical vapor deposition (MOCVD), single wafer etch & clean and lithography technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.

To the extent that this news release discusses expectations or otherwise makes statements about the future, such statements are forward-looking and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include the risks discussed in the Business Description and Management’s Discussion and Analysis sections of Veeco’s Annual Report on Form 10-K for the year ended December 31, 2025 and in our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K and press releases. Veeco does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances after the date of such statements.

Veeco Contacts:
Investor Relations: Alex Delacroix | (516) 528-1020 | adelacroix@veeco.com
Media: Brenden Wright | (410) 984-2610 | bwright@veeco.com